Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia

  • Barrio, Oriol de
  • Ocón-Gabarró, Ingrid
  • Gusi-Vives, Mar
  • Collazo, Olga
  • Meler, Ainara
  • Romecín, Paola A.
  • Martínez-Moreno, Alba
  • Tejedor, Juan Ramón
  • Fraga, Mario F.
  • Schneider, Paulina
  • Bardini, Michela
  • Cazzaniga, Giovanni
  • Marschalek, Rolf
  • Stam, Ronald W.
  • Bueno, Clara
  • Menéndez, Pablo
  • Parra, Maribel
[Background]: Infants diagnosed with B cell acute lymphoblastic leukemia (B-ALL) and t(4;11) chromosomal rearrangement display poor therapeutic response, associated to the low expression of B lymphocyte factor HDAC7. This study was conceived to identify a therapeutic strategy for t(4;11) B-ALL that restores optimal HDAC7 expression., [Methods]: A multiomics approach in a large infant pro-B-ALL cohort was employed to identify HDAC7's repression mechanism. These data, combined with cell culture assays in a variety of pro-B-ALL cell lines with differential HDAC7 levels, led us to define a novel combination therapy. Murine leukemia models and ex vivo assays using patient-derived xenografts (PDX) were employed to assess the benefits of this therapy when incorporated to glucocorticoid-based chemotherapy., [Results]: Our data demonstrates that HDAC7 is epigenetically silenced by EZH2 and KMT2A::AFF1 fusion protein. Remarkably, the Menin-1 inhibitor MI-538 restores HDAC7 expression, and the effect is enhanced by class I HDAC inhibitor chidamide. This treatment drives leukemic pro-B cells towards a more differentiated state and impairs aberrant proliferation in an HDAC7-dependent manner. This newly identified therapy increases glucocorticoid sensitivity of PDX cells ex vivo, by repressing RUNX2 transcription factor. Finally, combining MI-538 and chidamide with standard chemotherapy reduces PDX cells engraftment in vivo and delays relapse., [Conclusions]: The combined therapy proposed, based on Menin-1 inhibition, improves t(4;11) B-ALL cells' response to standard therapy, an effect partially mediated by HDAC7 induction. Therefore, this novel therapy opens a new field for personalized treatments in high-risk leukemia, especially for infants presenting low expression of HDAC7 B cell factor., This work was supported by the Spanish Ministry of Science and Innovation (MICINN, EUR2019-103835), Instituto de Salud Carlos III (ISCIII, PI21/01451), Deutsche José Carreras Leukämie Stiftung (DJCLS/07R/2022) and elaborated at the Josep Carreras Leukaemia Research Institute (IJC, Badalona, Barcelona). This project was also supported by the Fight Kids Cancer Funding Programme (Cure2MLL project), supported by Imagine For Margo, Fondation KickCancer, Foundatioun Kriibskrank Kanner, Federazione Italiana Associazioni Genitori e Guariti Oncoematologia Pediatrica and Cris Cancer Foundation. We thank CERCA Programme/Generalitat de Catalunya for institutional support. OdB was funded by a Postdoctoral Fellowship from the Asociación Española Contra el Cáncer (AECC) Foundation (POSTD20024DEBA) and by a Ramón y Cajal contract from the Spanish Ministry of Science, Innovation and Universities (RYC2021-031197-I). MG-V’s salary was funded by DJCLS/07R/2022 project. AM was funded by the Spanish Ministry of Science, Innovation and Universities, which is part of the Agencia Estatal de Investigación (AEI), through grant PRE2018-083183 (cofunded by the European Social Fund). JRT is supported by a Ramón y Cajal contract (RYC2021-031799-I) and the Asociación Galbán. Research in PM laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665); H2020 (101,057,250-CANCERNA), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and FEDER Funds, and CPP2021-008508, CPP2021-008676, CPP2022-009759 funded by MICIU/AEI/10.13039/501,100,011,033 and the European Union NextGenerationEU/PRTR); “Ayudas Merck de Investigación” from Health Merck Foundation; the Spanish Association Against Cancer (AECC, PRYGN234975MENE, PRYGN211192BUEN) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Additional funding was provided to CB by the Uno Entre Cien Mil Foundation, MINECO PLE2021-007518, Deutsche José Carreras Leukämie Stiftung (DJCLS/02R/2023) and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MYC's Fine Line Between B Cell Development and Malignancy

  • de Barrios, Oriol|||0000-0001-5076-1455
  • Meler, Ainara|||0000-0002-0026-7325
  • Parra, Maribel|||0000-0002-9072-5763
The transcription factor MYC is transiently expressed during B lymphocyte development, and its correct modulation is essential in defined developmental transitions. Although temporary downregulation of MYC is essential at specific points, basal levels of expression are maintained, and its protein levels are not completely silenced until the B cell becomes fully differentiated into a plasma cell or a memory B cell. MYC has been described as a proto-oncogene that is closely involved in many cancers, including leukemia and lymphoma. Aberrant expression of MYC protein in these hematological malignancies results in an uncontrolled rate of proliferation and, thereby, a blockade of the differentiation process. MYC is not activated by mutations in the coding sequence, and, as reviewed here, its overexpression in leukemia and lymphoma is mainly caused by gene amplification, chromosomal translocations, and aberrant regulation of its transcription. This review provides a thorough overview of the role of MYC in the developmental steps of B cells, and of how it performs its essential function in an oncogenic context, highlighting the importance of appropriate MYC regulation circuitry.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic control of infant b cell precursor acute lymphoblastic leukemia

  • de Barrios, Oriol|||0000-0001-5076-1455
  • Parra, Maribel|||0000-0002-9072-5763
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a highly aggressive malig-nancy, with poorer prognosis in infants than in adults. A genetic signature has been associated with this outcome but, remarkably, leukemogenesis is commonly triggered by genetic alterations of embryonic origin that involve the deregulation of chromatin remodelers. This review considers in depth how the alteration of epigenetic profiles (at DNA and histone levels) induces an aberrant phenotype in B lymphocyte progenitors by modulating the oncogenic drivers and tumor suppres-sors involved in key cancer hallmarks. DNA methylation patterns have been widely studied in BCP- ALL and their correlation with survival has been established. However, the effect of methylation on histone residues can be very different. For instance, methyltransferase KMT2A gene participates in chromosomal rearrangements with several partners, imposing an altered pattern of methylated H3K4 and H3K79 residues, enhancing oncogene promoter activation, and conferring a worse outcome on affected infants. In parallel, acetylation processes provide an additional layer of epigenetic regulation and can alter the chromatin conformation, enabling the binding of regulatory factors. Therefore, an integrated knowledge of all epigenetic disorders is essential to understand the molecular basis of BCP-ALL and to identify novel entry points that can be exploited to improve therapeutic options and disease prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The HDAC7-TET2 epigenetic axis is essential during early B lymphocyte development

  • Azagra, Alba|||0000-0002-9097-1251
  • Meler, Ainara|||0000-0002-0026-7325
  • de Barrios, Oriol|||0000-0001-5076-1455
  • Tomás Daza, Laureano|||0000-0002-6127-1694
  • Collazo, Olga
  • Monterde, B.
  • Obiols, Mireia|||0000-0003-3323-5239
  • Rovirosa Mulet, Llorenç|||0000-0003-2986-9001
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Cabrera Pasadas, Mònica|||0000-0001-9216-0906
  • Gusi Vives, Mar|||0000-0001-5702-153X
  • Graf, Thomas|||0000-0003-2774-4117
  • Varela, Ignacio|||0000-0002-0969-506X
  • Sardina, José Luis|||0000-0002-8493-3937
  • Javierre, B. M.|||0000-0002-8682-6748
  • Parra, Maribel|||0000-0002-9072-5763
Correct B cell identity at each stage of cellular differentiation during B lymphocyte development is critically dependent on a tightly controlled epigenomic landscape. We previously identified HDAC7 as an essential regulator of early B cell development and its absence leads to a drastic block at the pro-B to pre-B cell transition. More recently, we demonstrated that HDAC7 loss in pro-B-ALL in infants associates with a worse prognosis. Here we delineate the molecular mechanisms by which HDAC7 modulates early B cell development. We find that HDAC7 deficiency drives global chromatin de-condensation, histone marks deposition and deregulates other epigenetic regulators and mobile elements. Specifically, the absence of HDAC7 induces TET2 expression, which promotes DNA 5-hydroxymethylation and chromatin de-condensation. HDAC7 deficiency also results in the aberrant expression of microRNAs and LINE-1 transposable elements. These findings shed light on the mechanisms by which HDAC7 loss or misregulation may lead to B cell-based hematological malignancies.